All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Modified chemotherapy for pediatric patients with Down syndrome and high-risk B-ALL
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke with Karen Rabin, Texas Children’s Hospital, Houston, US. We asked, Can modified chemotherapy regimens improve outcomes for pediatric patients with Down syndrome and high-risk B-ALL?
Modified chemotherapy for pediatric patients with Down syndrome and high-risk B-ALL
Rabin highlights the poor historical outcomes for patients with Down syndrome, including an increased risk of relapse and treatment-related mortality. The prior Children’s Oncology Group trial AALL0232 (NCT00075725) was terminated due to excessive treatment-related mortality due to sepsis and profound neutropenia.
Rabin then discusses data from the recent AALL1131 trial (NCT02883049) investigating a modified chemotherapy regimen to increase safety and improve outcomes; modifications included changing four-drug to three-drug induction, leucovorin rescue after intrathecal methotrexate, modified intravenous methotrexate during interim maintenance, and enhanced supportive care guidelines.
Your opinion matters
2 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox